- Home
- GLRE vs UPB Comparison
GLRE vs UPB Comparison
Compare GLRE & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- UPB
- Stock Information
- Founded
- GLRE 2004
- UPB 2021
- Country
- GLRE Cayman Islands
- UPB United States
- Employees
- GLRE N/A
- UPB N/A
- Industry
- GLRE Property-Casualty Insurers
- UPB
- Sector
- GLRE Finance
- UPB
- Exchange
- GLRE Nasdaq
- UPB NYSE
- Market Cap
- GLRE 469.0M
- UPB 521.3M
- IPO Year
- GLRE 2007
- UPB 2024
- Fundamental
- Price
- GLRE $13.57
- UPB $8.82
- Analyst Decision
- GLRE
- UPB Strong Buy
- Analyst Count
- GLRE 0
- UPB 4
- Target Price
- GLRE N/A
- UPB $56.50
- AVG Volume (30 Days)
- GLRE 74.9K
- UPB 323.9K
- Earning Date
- GLRE 05-07-2025
- UPB 05-06-2025
- Dividend Yield
- GLRE N/A
- UPB N/A
- EPS Growth
- GLRE N/A
- UPB N/A
- EPS
- GLRE 1.32
- UPB N/A
- Revenue
- GLRE $717,617,000.00
- UPB $2,296,000.00
- Revenue This Year
- GLRE N/A
- UPB N/A
- Revenue Next Year
- GLRE N/A
- UPB $0.99
- P/E Ratio
- GLRE $10.22
- UPB N/A
- Revenue Growth
- GLRE 2.79
- UPB N/A
- 52 Week Low
- GLRE $11.95
- UPB $5.14
- 52 Week High
- GLRE $15.82
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- GLRE 56.99
- UPB N/A
- Support Level
- GLRE $13.21
- UPB N/A
- Resistance Level
- GLRE $13.36
- UPB N/A
- Average True Range (ATR)
- GLRE 0.31
- UPB 0.00
- MACD
- GLRE 0.05
- UPB 0.00
- Stochastic Oscillator
- GLRE 82.28
- UPB 0.00
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.